Diagmicoll: Collection of Human Biological Samples for the Development and Validation of New Methods of Diagnosis and for the Realization of Expertises Diagnostics in the Field of Infectious Diseases and Tropical

Sponsor
Institut Pasteur (Industry)
Overall Status
Unknown status
CT.gov ID
NCT03912246
Collaborator
(none)
800
2
2
140.2
400
2.9

Study Details

Study Description

Brief Summary

Direct constitution of collections from various samples taken on a prospective cohort of healthy volunteers, to prepare human biological samples of known characteristics (biochemical and serological in particular) and quality controlled.

Condition or Disease Intervention/Treatment Phase
  • Biological: biological samples
  • Procedure: lumbar puncture
N/A

Detailed Description

Direct constitution of collection from various samples taken on a prospective cohort of healthy volunteers, to prepare human biological samples of known characteristics (biochemical and serological in particular) and quality controlled.

This collection will allow, as a priority, a development stage, ie the establishment of the proof of concept of new diagnostic methods in the field of infectious and tropical diseases.

There will be 2 cohorts (= arms) for this study: the main cohort of healthy volunteers and the N cohort, which will consist of patients with neuro-meningeal disease of infectious appearance and followed in specialized consultation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
800 participants
Allocation:
Non-Randomized
Intervention Model:
Factorial Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Collection d'échantillons Biologiques Humains de Sujets Sains et Malades Pour la Mise au Point et la Validation de Nouvelles méthodes de Diagnostic et Pour la réalisation d'Expertises Dans le Domaine Des Maladies Infectieuses et Tropicales
Actual Study Start Date :
Apr 27, 2009
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Healthy volunteers

Human biological samples: whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs. Bio-clinical data : adjusted to the purpose of the searches will be collected

Biological: biological samples
collection of blood, urine, saliva, stool, skin and mouth swabs, tears

Experimental: Patients with neuro-meningeal infection

Human biological samples: Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs. Extended collection of CSF Bio-clinical data : adjusted to the purpose of the searches will be collected

Biological: biological samples
collection of blood, urine, saliva, stool, skin and mouth swabs, tears

Procedure: lumbar puncture
collection of cerebrospinal fluid

Outcome Measures

Primary Outcome Measures

  1. development of new diagnostic methods [during all the study]

    This collection will allow, as a priority, a first stage of development, that is to say the completion of the proof of concept of new diagnostic methods in the field of infectious and tropical diseases.

Secondary Outcome Measures

  1. performance improvement [during all the study]

    In a second step, the collection will be able to improve the essential performances (sensitivity and specificity) of the methods to the study compared to the existing methods: speed, simplicity (molecular methods, etc) and cost; and may also uncover new non-infectious biomarkers.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • major subject

  • affiliated or benefiting from social security

  • having signed the information and consent form

  • negative HIV and HCV serology and negative HBV or vaccine serology (or old healed infection profile)

  • for cohort N: neuromeningeal infection during dianostic exploration

Exclusion Criteria:
  • Volunteers with a severe or chronic pathology significantly disturbing one or more bio-clinical parameters and / or requiring the regular intake of certain drugs (anti-inflammatories or corticosteroids for example).

  • Woman whose pregnancy is known during the visit.

  • Acute infection within 15 days or taking antiviral, antibiotic, antifungal or antiparasitic drugs in the last 15 days.

  • Subject participating in a biomedical research or in a period of exclusion of a biomedical research.

  • When monitoring O +, AB +, A + and B + blood group whose erythrocyte base is kept for CEPIA research, in case of antimalarial (travel), a minimum of 5 half-lives after the last dose of antimalaria.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre d'infectiologie, hopitale Necker Paris France 75015
2 Institut Pasteur Paris France 75015

Sponsors and Collaborators

  • Institut Pasteur

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Institut Pasteur
ClinicalTrials.gov Identifier:
NCT03912246
Other Study ID Numbers:
  • 2008-16
  • DC-2008-68
First Posted:
Apr 11, 2019
Last Update Posted:
Jun 7, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Institut Pasteur
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 7, 2019